Inserm, U1043, Toulouse, France.
PLoS One. 2013 Jul 24;8(7):e69791. doi: 10.1371/journal.pone.0069791. Print 2013.
Although transplantation is the common treatment for end-stage renal failure, allograft rejection and marked morbidity from the use of immunosuppressive drugs remain important limitations. A major challenge in the field is to identify easy, reliable and noninvasive biomarkers allowing the prediction of deleterious alloreactive immune responses and the tailoring of immunosuppressive therapy in individuals according to the rejection risk. In this study, we first established that the expression of the RC isoform of the CD45 molecule (CD45RC) on CD4 and CD8 T cells from healthy individuals identifies functionally distinct alloreactive T cell subsets that behave differently in terms of proliferation and cytokine secretion. We then investigated whether the frequency of the recipients CD45RC T cell subsets before transplantation would predict acute graft rejection in a cohort of 89 patients who had undergone their first kidney transplantation. We showed that patients exhibiting more than 54.7% of CD8 CD45RC(high) T cells before transplantation had a 6 fold increased risk of acute kidney graft rejection. In contrast, the proportions of CD4 CD45RC T cells were not predictive. Thus, a higher risk of acute rejection of human kidney allografts can be predicted from the level of CD45RC expressed by the recipients' CD8 T cells.
尽管移植是治疗终末期肾衰竭的常用方法,但同种异体排斥反应和免疫抑制药物的显著发病率仍然是重要的限制因素。该领域的一个主要挑战是识别简单、可靠和非侵入性的生物标志物,以便根据排斥风险预测有害的同种反应性免疫反应,并根据个体的免疫抑制治疗进行调整。在这项研究中,我们首先确定了来自健康个体的 CD4 和 CD8 T 细胞上 CD45 分子的 RC 同工型(CD45RC)的表达,可识别功能上不同的同种反应性 T 细胞亚群,这些亚群在增殖和细胞因子分泌方面表现不同。然后,我们调查了在接受首次肾移植的 89 名患者队列中,受体 CD45RC T 细胞亚群在移植前的频率是否可以预测急性移植物排斥反应。我们发现,移植前 CD8 CD45RC(高)T 细胞超过 54.7%的患者发生急性肾移植物排斥的风险增加了 6 倍。相比之下,CD4 CD45RC T 细胞的比例没有预测性。因此,受体 CD8 T 细胞表达的 CD45RC 可预测人类肾同种异体移植物的急性排斥反应风险增加。